# Compare the Claim, Not Just the Compound

> Compare Four Peptide Evidence Files — Research Peptide Fundamentals — Research Peptide Fundamentals research peptides compared by mechanism, human evidence, population, certainty, safety, and regulatory scope.

**EVIDENCE DESK / CROSS-FILE**

Four mechanisms placed beside four evidence bases, with population and uncertainty kept in view.

## The short version

These four peptides do not belong in a simple best-to-worst ranking. They ask different biological questions and arrive with different kinds of evidence. Tesamorelin stimulates the body’s growth-hormone relay and has controlled human data in HIV-associated lipodystrophy. Semaglutide activates GLP-1 receptors and has large outcome trials across several clinical populations. PT-141 activates central melanocortin receptors and has controlled trials for a narrowly defined sexual-desire disorder. BPC-157 is studied for repair pathways, but its record remains mostly laboratory and animal work.

A fair comparison therefore uses four columns: mechanism, population, endpoint, and study design. The same peptide can earn a strong grade for one claim and a weak grade for another. Approval also has boundaries; it does not turn off-label theories into established findings. The table is a map of what each evidence file can presently support, not advice about which compound anyone should use.

## At-a-glance evidence map

| Compound | Main signal | Best-developed evidence here | Present evidence reading |
|---|---|---|---|
| **Tesamorelin** | Pituitary GHRH receptor → GH/IGF-1 axis | Randomized human studies and pooled trials in HIV-associated lipodystrophy [1][3] | Strong for visceral-fat outcomes in that population; limited generalization |
| **Semaglutide** | GLP-1 receptor across pancreas, gut, and appetite circuits | Large randomized weight, cardiovascular, and kidney outcome trials [9][10][11] | Broad, mature human evidence with defined safety tradeoffs |
| **PT-141** | Central MC4R/MC3R melanocortin signaling | Phase 3 trials in premenopausal women with acquired, generalized HSDD [15] | Moderate-to-strong for a narrow indication; off-label claims remain weaker |
| **BPC-157** | VEGFR2/Akt/eNOS and other repair pathways | Animal and cell studies; tiny human pilots [18][19][21] | Mechanistically interesting, clinically unresolved |

The final column deliberately avoids a single letter grade. Evidence quality attaches to a claim. A large trial of one outcome cannot answer every safety question, while a careful cell study can strongly support receptor activity without supporting human benefit.

## Mechanisms are maps, not verdicts

Tesamorelin is an upstream messenger. It presses the GHRH receptor and lets the pituitary release endogenous growth hormone in pulses, leading to IGF-1 production and effects on visceral fat. Semaglutide is a distributed appetite-and-metabolism signal, acting through GLP-1 receptors in the pancreas, gut, and brain. PT-141 works centrally through melanocortin receptors linked to desire and arousal processing. BPC-157 is proposed to support repair through blood-vessel and cell-migration pathways.

Each mechanism is plausible within the source record, but plausibility is not clinical proof. BPC-157 offers the clearest warning: VEGFR2 signaling and improved blood flow in models do not establish tendon healing in people [21]. PT-141 imaging connects MC4R agonism to brain processing, yet the clinical conclusion still depends on controlled patient outcomes [14][15]. Tesamorelin and semaglutide show the same rule from the other direction: trial outcomes are real even when no single downstream pathway explains every effect.

## How mature is the human evidence?

Semaglutide has the widest record in this collection. The selected trials include 1,961 participants for weight change, 17,604 for cardiovascular outcomes, and 3,533 for kidney outcomes [9][10][11]. That range supports conclusions across several defined populations and endpoints, while leaving individual prediction outside the study’s reach.

Tesamorelin has multiple controlled trials and a meta-analysis, but the central population is adults with HIV-associated lipodystrophy [1]. The evidence is not weak; it is narrow. PT-141 has two Phase 3 trials with 1,267 participants and an open-label extension, creating a meaningful record for the approved HSDD population [15][16]. Again, the boundary is demographic and diagnostic.

BPC-157 sits on a different rung. A two-person safety pilot observed no adverse events, while a review identified only three human pilots and no rigorous large-scale studies [18][19]. That is insufficient for a human efficacy claim. The comparison shows why “human study exists” is not a useful binary. Size, control, blinding, endpoint, and replication determine what the study can bear.

## Safety and guidance read differently at each rung

With semaglutide, common gastrointestinal effects and biliary risk appear within a large clinical record, while rarer pancreatic and thyroid questions remain less certain [12]. PT-141 has labeled warnings for transient blood-pressure increases and defined tolerability data, including nausea, flushing, and headache [16][17]. Tesamorelin’s selected record includes GH/IGF-1 elevation, reaccumulation of visceral fat after discontinuation, and limited duration for longer-term inference [4][5].

BPC-157 lacks enough human exposure to estimate a dependable safety profile. Its angiogenic mechanism also creates theoretical questions that human studies have not resolved [19][21]. Here, “no observed problem” in a tiny pilot means something very different from “risk characterized” in a large program.

Guidance documents and labels are useful because they turn a body of evidence into scoped language: indication, population, warning, contraindication, and uncertainty. They are not endorsements, and this site does not present boards or experts as authorities. The cited record remains visible so the strength of each statement can be checked.

## A practical reading rule

When a peptide claim appears, the first question is not “Does the compound work?” It is “What exact result, in what model or population, compared with what, and for how long?” Tesamorelin’s visceral-fat evidence, semaglutide’s outcome trials, PT-141’s desire endpoints, and BPC-157’s repair mechanisms can all be accurately reported without pretending they answer the same question.

The second rule is to keep uncertainty visible. Null animal findings, treatment discontinuation effects, common adverse reactions, and lack of replication belong beside positive outcomes [5][13][19]. The third is to separate a regulated studied product from unverified material carrying the same compound name.

That approach produces fewer sweeping answers, but better ones. Each [compound file](/tesamorelin) provides the deeper reading, and the [reference ledger](/references) supplies the source trail.

---

Peptide Evidence Review is an independent reading desk for grading peptide claims—literature and context, never a storefront or medical direction.